# ChangE From Any Systemic psoriasiS therapY to Raptiva

> **NCT00697593** · PHASE4 · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 70 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)

## Key facts

- **NCT ID:** NCT00697593
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union
- **Last updated:** 2014-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697593, "ChangE From Any Systemic psoriasiS therapY to Raptiva". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00697593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*